Patents Examined by Irina Neagu
  • Antimicrobial preservative compositions for personal care products
    Patent number: 9661847
    Abstract: A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided and includes [A] one or more undecylenic acid derivatives depicted by Formula (I), [B] one or more octanoic acid derivatives depicted by Formula (II), and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two ‘liquid alcohol ethers’; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the ‘liquid alcohol ether’, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: May 30, 2017
    Assignee: Galaxy Surfactants Ltd.
    Inventors: Nirmal Koshti, Shraddha Kiran Ratnaparkhe, Devyani Ashok Mali, Bhagyesh Sawant, Pooja Dinkar Vaidya
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9663460
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: May 30, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
  • Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
    Patent number: 9662322
    Abstract: This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 30, 2017
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventor: Volker Knappertz
  • Tetrahydropyridopyrimidine compound or salt thereof
    Patent number: 9662333
    Abstract: A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: May 30, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa Minamiguchi, Shigeo Okajima, Shinichi Aoki, Masanori Asai, Takahiro Asai, Hiroyoshi Yamanaka, Suguru Dohi
  • Treatment of prostate carcinoma
    Patent number: 9655868
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 23, 2017
    Assignee: Pellficure Pharmaceuticals, Inc.
    Inventor: Per Borgström
  • Inhibition of renal fibrosis
    Patent number: 9572787
    Abstract: The invention provides compositions and methods for inhibiting renal fibrosis.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 21, 2017
    Assignee: Rhode Island Hospital
    Inventor: Shougang Zhuang
  • Cell permeable inhibitors of anaphase promoting complex
    Patent number: 9572788
    Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: February 21, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Randall King, Xing Zeng, Katharine L. Sackton
  • Methods and compositions for treating pain
    Patent number: 9545393
    Abstract: Methods and compositions are provided for treating pain in an individual. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. These methods find many uses, for example in treating and preventing nociceptive pain, inflammatory pain, and neuropathic pain.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: January 17, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Vanessa Zambelli, Che-Hong Chen, Daria Mochly-Rosen
  • Antimicrobial composition
    Patent number: 9504248
    Abstract: The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising one or more monosubstituted phenols, terpineol and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: November 29, 2016
    Assignee: Rohm and Haas Company
    Inventors: Robert J. Cornmell, Megan A. Diehl, Stephen Golding, John R. Harp, Ian P. Stott, Katherine M. Thompson, Carol L. Truslow
  • Methods for reducing body fat
    Patent number: 9504695
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: November 29, 2016
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Methods for treating polycystic kidney disease
    Patent number: 9457016
    Abstract: Methods for treating autosomal dominant polycystic kidney disease (ADPKD) are described herein. More particularly, methods described herein relate generally to administering glutaminase1 inhibitors to subjects afflicted with ADPKD. Accordingly, the use and application of compounds or agents that inhibit glutaminase1 for treating ADPKD or for use in a medicament for treating ADPKD are encompassed herein.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: October 4, 2016
    Assignee: New York University
    Inventors: Edward Skolnik, Zhai Li
  • Formylated xanthocillin analogues as neuroprotective agents
    Patent number: 9453004
    Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: September 27, 2016
    Assignee: NEURON BIOPHARMA, S.A.
    Inventors: Maria del Carmen Ramos Martin, Sonia Campoy Garcia, Javier Santos Burgos Muñoz, José Luis Adrio Fondevila, Javier Velasco Alvarez
  • Methods and compositions for treating degenerative and ischemic disorders
    Patent number: 9399032
    Abstract: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: July 26, 2016
    Assignee: The General Hospital Corporation
    Inventors: Vamsi K. Mootha, Vishal Gohil, Sunil Sheth, Yuhua Ji
  • Indole and indazole compounds that activate AMPK
    Patent number: 9394285
    Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: July 19, 2016
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Kimberly O'Keefe Cameron, Matthew Scott Dowling, David Christopher Ebner, David James Edmonds, Dilinie Prasadhini Fernando, Kevin James Filipski, Daniel Wei-Shung Kung, Esther Cheng Yin Lee, Aaron Christopher Smith, Meihua Mike Tu
  • Method of identifying therapies for pulmonary hypertension
    Patent number: 9387214
    Abstract: The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 12, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Randy Stephen Sprague, Alan Howard Stephenson, Mary Litchfield Ellsworth, Elizabeth A. Bowles
  • Serine/threonine kinase inhibitors
    Patent number: 9388171
    Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: July 12, 2016
    Assignees: GENETECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
  • Pyrimido-pyridazinone compounds and methods of use thereof
    Patent number: 9382277
    Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: July 5, 2016
    Assignee: Asana Biosciences, LLC
    Inventors: Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
  • Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals
    Patent number: 9381169
    Abstract: The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. The present invention further relates to the use of said polyfunctional metal phenolates in the preparation of drugs for the treatment, prophylaxis or prevention of neoplasic diseases in humans and animals.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: July 5, 2016
    Assignees: UNIVERSIDADE BANDEIRANTE DE SÃO PAULO—ACADEMIA PAULISTA ANCHIETA S/C LT, FUNDAÇ ÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO—FAPESP
    Inventors: José Agustin Quincoces Suárez, Durvanei Augusto Maria, Paulo Celso Pardi, Fernanda Faião Flores, Reginaldo Pereira Santos, Daniela Gonçales Rando
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9371278
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9365577
    Abstract: Pyrimidinone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HINE is implicated.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 14, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi